» Articles » PMID: 37097265

Non-clinical, Quality and Environmental Impact Assessments of Cell and Gene Therapy Products: Report on the 5th Asia Partnership Conference of Regenerative Medicine - April 7, 2022

Abstract

The 5th Asia Partnership Conference of Regenerative Medicine (APACRM) was held online on April 7, 2022 to promote regulatory harmonization of regenerative medicine products throughout Asia. The recognition of domestic regulatory guidelines within each country and region and the underpinning rationales are important initial steps toward the harmonization of regulations. The 5th APACRM featured open dialog regarding non-clinical, quality and environmental impact assessment settings for cell and gene therapy products through presentations from the industry and panel discussions with regulatory agencies. The latest updates on regenerative medicine fields in each country and region were also introduced. This paper summarizes the proceedings of the 5th APACRM for public dissemination to foster future discussion.

Citing Articles

Regulatory insights on advanced CAR-T cell products, AAV-based Gene therapies, and medical care/practice in cell and Gene therapies: Report from the 6th Asia partnership conference of regenerative medicine- April 20, 2023.

Karasawa H, Mizoguchi H, Choi B, Hsieh C, Miyano M, Moriya Y Regen Ther. 2024; 26:967-980.

PMID: 39524180 PMC: 11550569. DOI: 10.1016/j.reth.2024.09.015.